BACKGROUND: Straub et al. (2002b) located a susceptibility region for schizophrenia at the DTNBP1 locus. At least 40 studies (including one study in US populations) attempted to replicate this original finding, but the reported findings are highly diverse and at least five pathways by which dysbindin protein might be involved in schizophrenia have been proposed. This study aimed to test the association in two common US populations by using powerful analytic methods. METHODS: Six markers at DTNBP1 were genotyped by mass spectroscopy ('MassARRAY' technique) in a sample of 663 individuals, including 346 healthy individuals European-Americans (EAs) and 48 African-Americans (AAs), and 317 individuals with schizophrenia (235 EAs and 82 AAs). Thirty-eight ancestry-informative markers were genotyped in this sample to infer the ancestry proportions. Diplotype, haplotype, genotype, and allele frequency distributions were compared between the cases and controls, controlling for possible population stratification, admixture, and sex-specific effects, and taking interaction effects into account, using a logistic regression analysis (an extended structured association method). RESULTS: Conventional case-control comparisons showed that genotypes of the markers P1578 (rs1018381) and P1583 (rs909706) were nominally associated with schizophrenia in EAs and in AAs, respectively. These associations became less or nonsignificant after controlling for population stratification and admixture effects (using structured association or regression analysis), and became nonsignificant after correction for multiple testing. However, regression analysis showed that the common diplotypes (ACCCTT/GCCGCC or GCCGCC/GCCGCC) and the interaction effects of haplotypes GCCGCC/GCCGCC significantly affected risk for schizophrenia in EAs, effects that were modified by sex. Fine-mapping using d or J statistics located the specific markers (d: P1328; J: P1333) closest to the putative risk sites in EAs. CONCLUSION: This study shows that DTNBP1 is a risk gene for schizophrenia in EAs. Variation at DTNBP1 may modify risk for schizophrenia in this population.
BACKGROUND: Straub et al. (2002b) located a susceptibility region for schizophrenia at the DTNBP1 locus. At least 40 studies (including one study in US populations) attempted to replicate this original finding, but the reported findings are highly diverse and at least five pathways by which dysbindin protein might be involved in schizophrenia have been proposed. This study aimed to test the association in two common US populations by using powerful analytic methods. METHODS: Six markers at DTNBP1 were genotyped by mass spectroscopy ('MassARRAY' technique) in a sample of 663 individuals, including 346 healthy individuals European-Americans (EAs) and 48 African-Americans (AAs), and 317 individuals with schizophrenia (235 EAs and 82 AAs). Thirty-eight ancestry-informative markers were genotyped in this sample to infer the ancestry proportions. Diplotype, haplotype, genotype, and allele frequency distributions were compared between the cases and controls, controlling for possible population stratification, admixture, and sex-specific effects, and taking interaction effects into account, using a logistic regression analysis (an extended structured association method). RESULTS: Conventional case-control comparisons showed that genotypes of the markers P1578 (rs1018381) and P1583 (rs909706) were nominally associated with schizophrenia in EAs and in AAs, respectively. These associations became less or nonsignificant after controlling for population stratification and admixture effects (using structured association or regression analysis), and became nonsignificant after correction for multiple testing. However, regression analysis showed that the common diplotypes (ACCCTT/GCCGCC or GCCGCC/GCCGCC) and the interaction effects of haplotypes GCCGCC/GCCGCC significantly affected risk for schizophrenia in EAs, effects that were modified by sex. Fine-mapping using d or J statistics located the specific markers (d: P1328; J: P1333) closest to the putative risk sites in EAs. CONCLUSION: This study shows that DTNBP1 is a risk gene for schizophrenia in EAs. Variation at DTNBP1 may modify risk for schizophrenia in this population.
Authors: Clive J Hoggart; Eteban J Parra; Mark D Shriver; Carolina Bonilla; Rick A Kittles; David G Clayton; Paul M McKeigue Journal: Am J Hum Genet Date: 2003-06 Impact factor: 11.025
Authors: Xingguang Luo; Henry R Kranzler; Hongyu Zhao; Joel Gelernter Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2003-07-01 Impact factor: 3.568
Authors: J X Tang; J Zhou; J B Fan; X W Li; Y Y Shi; N F Gu; G Y Feng; Y L Xing; J G Shi; L He Journal: Mol Psychiatry Date: 2003-08 Impact factor: 15.992
Authors: James J Crowley; David W Oslin; Ashwin A Patkar; Edward Gottheil; Peter A DeMaria; Charles P O'Brien; Wade H Berrettini; Dorothy E Grice Journal: Psychiatr Genet Date: 2003-09 Impact factor: 2.458
Authors: E J C G van den Oord; P F Sullivan; Y Jiang; D Walsh; F A O'Neill; K S Kendler; B P Riley Journal: Mol Psychiatry Date: 2003-05 Impact factor: 15.992
Authors: N M Williams; A Preece; G Spurlock; N Norton; H J Williams; S Zammit; M C O'Donovan; M J Owen Journal: Mol Psychiatry Date: 2003-05 Impact factor: 15.992
Authors: Cathryn M Lewis; Douglas F Levinson; Lesley H Wise; Lynn E DeLisi; Richard E Straub; Iiris Hovatta; Nigel M Williams; Sibylle G Schwab; Ann E Pulver; Stephen V Faraone; Linda M Brzustowicz; Charles A Kaufmann; David L Garver; Hugh M D Gurling; Eva Lindholm; Hilary Coon; Hans W Moises; William Byerley; Sarah H Shaw; Andrea Mesen; Robin Sherrington; F Anthony O'Neill; Dermot Walsh; Kenneth S Kendler; Jesper Ekelund; Tiina Paunio; Jouko Lönnqvist; Leena Peltonen; Michael C O'Donovan; Michael J Owen; Dieter B Wildenauer; Wolfgang Maier; Gerald Nestadt; Jean-Louis Blouin; Stylianos E Antonarakis; Bryan J Mowry; Jeremy M Silverman; Raymond R Crowe; C Robert Cloninger; Ming T Tsuang; Dolores Malaspina; Jill M Harkavy-Friedman; Dragan M Svrakic; Anne S Bassett; Jennifer Holcomb; Gursharan Kalsi; Andrew McQuillin; Jon Brynjolfson; Thordur Sigmundsson; Hannes Petursson; Elena Jazin; Tomas Zoëga; Tomas Helgason Journal: Am J Hum Genet Date: 2003-06-11 Impact factor: 11.025
Authors: Lingjun Zuo; Xingguang Luo; John H Krystal; Joyce Cramer; Dennis S Charney; Joel Gelernter Journal: Pharmacogenet Genomics Date: 2009-06 Impact factor: 2.089
Authors: Emilie I Petit; Zuzanna Michalak; Rachel Cox; Colm M P O'Tuathaigh; Niamh Clarke; Orna Tighe; Konrad Talbot; Derek Blake; Josephine Joel; Alexander Shaw; Steven A Sheardown; Alastair D Morrison; Stephen Wilson; Ellen M Shapland; David C Henshall; James N Kew; Brian P Kirby; John L Waddington Journal: Neuropsychopharmacology Date: 2016-12-16 Impact factor: 7.853
Authors: Konrad Talbot; Natalia Louneva; Julia W Cohen; Hala Kazi; Derek J Blake; Steven E Arnold Journal: PLoS One Date: 2011-03-01 Impact factor: 3.240
Authors: S Trost; B Platz; J Usher; H Scherk; T Wobrock; S Ekawardhani; J Meyer; W Reith; P Falkai; O Gruber Journal: Eur Arch Psychiatry Clin Neurosci Date: 2012-05-13 Impact factor: 5.270
Authors: Marjan Huizing; May C V Malicdan; Jennifer A Wang; Hadass Pri-Chen; Richard A Hess; Roxanne Fischer; Kevin J O'Brien; Melissa A Merideth; William A Gahl; Bernadette R Gochuico Journal: Hum Mutat Date: 2020-01-23 Impact factor: 4.700